Overview

Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients

Status:
Unknown status

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The main purpose of this research study is to investigate how well a medicine (alemtuzumab) works in treating MS-related cognitive problems (e.g., attention, memory, speed of thinking). This study will include 30 subjects from six research sites. Alemtuzumab is approved and sold under the brand names Campath and MabCampath to treat some types of leukemia. As a leukemia treatment, it is given more often and at much higher doses than in this study.

Phase:

Phase 3

Details

Lead Sponsor:

Central Texas Neurology Consultants

Collaborator:

Genzyme, a Sanofi Company

Treatments:

Alemtuzumab